Author: Bella Hayes

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) — Cytokinetics (NASDAQ:), Incorporated  (: CYTK) today announced that Sanofi (EPA:) (NASDAQ:) will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals (CORXEL) for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) in Greater China. Aficamten is a next-in-class cardiac myosin inhibitor for the potential treatment of patients with HCM. In 2020, CORXEL (formerly Ji Xing) acquired the rights to develop and commercialize aficamten in Greater China (including the Chinese mainland, Hong Kong SAR and Macau SAR, and Taiwan) from Cytokinetics in accordance with Cytokinetics’ global…

(Reuters) – California’s utilities regulator on Thursday set a clear path toward potentially closing SoCalGas’s Aliso Canyon gas storage facility, prioritizing energy reliability and affordability as the state shifts to cleaner energy. The California Commission (CPUC) has set a natural gas peak demand target of 4,121 million cubic feet per day, marking the threshold at which Southern California can meet demand without Aliso Canyon, it said in a statement. Aliso Canyon, which serves more than 11 million customers and provides fuel to 17 natural gas-fired power plants, will be reviewed for permanent closure when the “forecasted peak day demand for…

DURHAM, N.C. – The U.S. Food and Drug Administration (FDA) has granted full approval to Humacyte, Inc.’s SYMVESS for use in adults requiring vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss and when autologous vein graft is not feasible. This marks a significant milestone in regenerative medicine and for the biotechnology company specializing in bioengineered human tissues. With a market capitalization of $443 million and trading near InvestingPro’s Fair Value estimate, Humacyte shows significant analyst optimism with price targets ranging from $6 to $25. SYMVESS, also known as acellular tissue engineered vessel-tyod,…

GuruFocus – Year-to-Date Revenue: $4.3 million, a 24% decrease from $5.7 million in the same period last year.Gross Margin: Negative 12% of revenue, compared to positive 25% in the same period last year.Cash Used in Operations: $12.5 million, an 11% increase compared to the same period last year.Cash and Accounts Receivable: Ended the quarter with $5.7 million.Additional Financing: Closed an additional $6 million financing post-quarter.Release Date: December 16, 2024For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Red Cat Holdings Inc (NASDAQ:RCAT) announced a new partnership with Palantir (NASDAQ:) to enhance…

In a recent transaction, Robert Andrew Berman, the Chief Executive Officer of enVVeno Medical (TASE:) Corp (NASDAQ:NVNO), purchased 12,000 shares of the company’s common stock. The shares were acquired at a weighted average price of approximately $2.55, with the total transaction valued at $30,599. The purchase comes as the stock trades near its 52-week low of $2.50, with technical indicators suggesting oversold conditions according to InvestingPro analysis. Following this acquisition, Berman’s direct ownership in the company increased to 222,236 shares. This purchase reflects Berman’s continued investment in the Irvine, California-based medical device company, which maintains a strong balance sheet with…

SAN FRANCISCO—Robin Howard, President and CEO of Nektar Therapeutics (NASDAQ:), recently sold shares of the company’s common stock, according to a recent SEC filing. The company’s stock has shown remarkable strength, posting a 98% gain over the past year, though InvestingPro analysis indicates the stock is currently trading below its Fair Value. The transactions, which took place on December 17 and 18, involved the sale of a total of 132,030 shares, resulting in proceeds of approximately $131,649. The shares were sold at prices ranging from $0.99 to $1.01 per share. Following these transactions, Howard retains ownership of 1,110,675 shares directly,…

GuruFocus – Revenue: Increased 2.1% to $125.7 million in Q4 and 10.7% for the fiscal year to $502.5 million.Recurring Revenue: Grew 1.1% to $88.2 million in Q4, representing 70.2% of total revenue; increased 16.4% for the fiscal year to $346.6 million.Net Income: $22.6 million in Q4, down from $25.1 million; $81.3 million for the fiscal year, up from $72.2 million.Adjusted EBITDA: Decreased to $35.6 million in Q4 with a 28.3% margin; $143.8 million for the fiscal year, up 7.5%.Cash Flow from Operating Activities: $40.3 million in Q4; $151.8 million for the fiscal year.Cash and Cash Equivalents: Increased to $274.2 million…

NEW YORK—Saba Capital Management, L.P. has recently increased its stake in Eaton (NYSE:) Vance New York Municipal Bond Fund (NYSE:ENX), a fund known for its 23-year track record of consistent dividend payments and current attractive yield of 5.22%, by acquiring additional shares. According to a recent SEC filing, Saba Capital purchased a total of 36,517 shares over two days, December 17 and December 18, 2024, with a total transaction value of approximately $354,118. The purchase prices ranged between $9.68 and $9.70 per share. The fund has demonstrated stable performance with a beta of 0.59, indicating lower volatility than the broader…

New York, New York–(Newsfile Corp. – December 19, 2024) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Celsius Holdings , Inc. (NASDAQ: NASDAQ:) between February 29, 2024 and September 4, 2024, both dates inclusive (the “Class Period”), of the important January 21, 2025 lead plaintiff deadline. SO WHAT: If you purchased Celsius common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Celsius class action, go to https://rosenlegal.com/submit-form/?case_id=31677…

These sales were conducted under a Rule 10b5-1 trading plan, which was adopted on January 4, 2024. As of the latest transaction, Canessa holds 217,423 shares of Zscaler (NASDAQ:) stock. For deeper insights into Zscaler’s valuation metrics and 12 additional exclusive ProTips, visit InvestingPro. For deeper insights into Zscaler’s valuation metrics and 12 additional exclusive ProTips, visit InvestingPro. These sales were conducted under a Rule 10b5-1 trading plan, which was adopted on January 4, 2024. As of the latest transaction, Canessa holds 217,423 shares of Zscaler stock. For deeper insights into Zscaler’s valuation metrics and 12 additional exclusive ProTips, visit…